NASDAQ: STLNStarling Oncology Inc Stock
$5.03-0.14 (-2.71%)
Updated Aug 5, 2026
STLN Price
$5.03
Fair Value Price
N/A
Market Cap
$512.64M
52 Week Low
$2.32
52 Week High
$6.66
P/E
0x
P/B
-20.58x
P/S
0.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$587.24M
Earnings
-$40.83M
Gross Margin
15.7%
Operating Margin
-5.65%
Profit Margin
-7%
Debt to Equity
-8.15
Operating Cash Flow
$328k
Beta
1.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
STLN Overview
The Oncology Institute Incorporated is an oncology company that provides physician services, in-house infusion and dispensary services, clinical trial services, radiation treatment services, outpatient stem cell transplants and transfusions programs, and patient support. The company also manages clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. through 67 clinics. The Oncology Institute was founded in 2007 and is based in Cerritos, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STLN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
STLN
Ranked#27 of 43
Ranked#27 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $26.08 | A | |
| $9.46 | A | |
| $549.48 | A |
Be the first to know about important STLN news, forecast changes, insider trades & much more!
STLN News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STLN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STLN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
STLN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more STLN due diligence checks available for Premium users.
Valuation
STLN fair value
Fair Value of STLN stock based on Discounted Cash Flow (DCF)
Price
$5.03
Fair Value
-$4.71
Undervalued by
206.81%
STLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
STLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
17.34x
Market
11.77x
STLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-20.58x
Industry
5.75x
STLN's financial health
Profit margin
Revenue
$161.3M
Net Income
-$8.2M
Profit Margin
-5.1%
STLN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
STLN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$178.2M
Liabilities
$203.1M
Debt to equity
-8.15
STLN's short-term assets ($128.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STLN's short-term assets ($128.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
STLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$11.9M
Investing
-$908.0k
Financing
-$218.0k
STLN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STLN vs Medical Care Facility Stocks
Starling Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.